List of Excipients in Branded Drug FELBAMATE

Generic Drugs Containing FELBAMATE

Company	Ingredient	NDC	Excipient
Pharmaceutical Associates Inc	felbamate	0121-0891	CARBOXYMETHYLCELLULOSE SODIUM
Pharmaceutical Associates Inc	felbamate	0121-0891	CELLULOSE, MICROCRYSTALLINE
Pharmaceutical Associates Inc	felbamate	0121-0891	CITRIC ACID MONOHYDRATE
Pharmaceutical Associates Inc	felbamate	0121-0891	DIMETHICONE
Pharmaceutical Associates Inc	felbamate	0121-0891	FD&C RED NO. 40
Pharmaceutical Associates Inc	felbamate	0121-0891	FD&C YELLOW NO. 6
Pharmaceutical Associates Inc	felbamate	0121-0891	GLYCERIN

What are the Most Frequently-Used Excipients in FELBAMATE?

# Of NDCs	Excipient
2	ALUMINUM OXIDE
2	BENZOIC ACID
6	CARBOXYMETHYLCELLULOSE SODIUM
19	CELLULOSE, MICROCRYSTALLINE
3	CITRIC ACID MONOHYDRATE
11	CROSCARMELLOSE SODIUM
4	D&C YELLOW NO. 10

Felbamate Excipient Strategy and Commercial Opportunities

Last updated: August 7, 2026

Felbamate is an established, low-volume antiseizure medicine with limited direct competition and a narrow commercial market. Its principal formulation opportunities are pediatric liquid optimization, improved palatability, dose flexibility, administration aids for patients with dysphagia, and supply-chain diversification. The main commercial constraint is the drug’s boxed warnings for aplastic anemia and hepatic failure, which limit prescribing and reduce the value of differentiated formulations.

The strongest near-term opportunity is a robust, palatable oral suspension or ready-to-administer liquid using well-characterized excipients, supported by improved dosing accuracy and lifecycle-management positioning. A reformulated product would face less intellectual-property risk than a new chemical entity but would require careful regulatory positioning, clinical bridging, extractables and leachables assessment, and justification that the new excipient system does not alter felbamate exposure or safety.

What is felbamate and how is it commercialized?

Felbamate is an oral antiseizure drug used for partial seizures in adults and for Lennox-Gastaut syndrome in children. It is marketed in tablets and oral suspension formulations. The U.S. product is associated with severe safety warnings and requires careful patient selection and monitoring of blood counts and liver function (U.S. Food and Drug Administration [FDA], 2024a).

Attribute	Felbamate
Active ingredient	Felbamate
Therapeutic class	Antiseizure medication
Primary dosage forms	Immediate-release tablets and oral suspension
Common tablet strengths	400 mg and 600 mg
Pediatric relevance	High, particularly in Lennox-Gastaut syndrome
Regulatory status	FDA-approved prescription drug
Key safety limitation	Aplastic anemia and hepatic failure
Primary formulation challenge	Palatability, dosing flexibility, and stable liquid delivery
Commercial market	Specialty, low-volume, medically complex

Felbamate is generally used when other antiseizure therapies have failed or are unsuitable. This creates a concentrated but clinically important market. Prescribers and caregivers value reliable administration, particularly for children receiving multiple medicines and patients who cannot swallow tablets.

What excipients are used in felbamate formulations?

The commercial excipient strategy differs materially between tablets and liquids. Tablets prioritize manufacturability, compression, disintegration, stability, and low cost. Suspensions require control of sedimentation, redispersibility, viscosity, microbial risk, taste, dosing accuracy, and container compatibility.

Public product labeling identifies inactive ingredients for approved felbamate products. Tablet formulations generally use conventional solid oral excipients such as fillers, binders, disintegrants, lubricants, and film-coating materials. Oral suspension formulations use a vehicle, suspending system, sweetener or taste-modifying system, preservative system, and pH-control agents (DailyMed, 2024).

Tablet excipient functions

Excipient function	Typical excipient classes	Commercial purpose
Dilution and tablet mass	Microcrystalline cellulose, starches, lactose or other fillers	Enables consistent tablet weight and dose uniformity
Binding	Hypromellose, povidone, pregelatinized starch	Improves granule and tablet strength
Disintegration	Sodium starch glycolate, crospovidone, croscarmellose sodium	Promotes tablet breakup after administration
Lubrication	Magnesium stearate, sodium stearyl fumarate	Reduces sticking and ejection force
Film coating	Hypromellose, polyethylene glycol, titanium dioxide or colorants	Improves handling, identification, and swallowability

A generic tablet manufacturer is unlikely to obtain a meaningful commercial advantage from routine excipient substitution alone. Most standard excipients are widely available, and a conventional immediate-release tablet is comparatively easy to replicate from a pharmaceutical-development perspective. The commercial value lies in manufacturing reliability, supply continuity, dose flexibility, and differentiated administration rather than in a novel tablet excipient.

Liquid excipient functions

A felbamate suspension requires a more complex excipient architecture:

Formulation requirement	Relevant excipient strategy
Uniform drug distribution	Suspending polymers and controlled particle size
Redispersibility	Xanthan gum, cellulose derivatives, or structured vehicles
Palatability	Sweeteners, flavors, pH adjustment, and taste-masking agents
Microbial protection	Preservatives or validated preservative-free packaging
Chemical stability	Buffer system, antioxidant where justified, oxygen control
Dosing accuracy	Controlled viscosity and oral syringe compatibility
Container compatibility	Low-sorption bottle, closure, and dosing-device system

Felbamate’s clinical use in children makes taste and administration performance commercially important. A suspension that settles rapidly, requires vigorous shaking, or has a bitter aftertaste creates avoidable adherence problems.

What formulation opportunities exist for felbamate?

The most credible opportunities are incremental dosage-form improvements rather than new delivery technologies.

Palatable pediatric oral suspension

A liquid product could target children with Lennox-Gastaut syndrome, patients with feeding tubes, and adults with dysphagia. The formulation should prioritize:

• Fast and complete redispersion after storage.
• Consistent dose delivery through an oral syringe.
• Low viscosity during withdrawal from the bottle.
• Acceptable taste after repeated dosing.
• Preservative effectiveness across the labeled in-use period.
• Stability under normal household storage conditions.

Taste masking is likely to be a central development issue. Formulators can evaluate sweetener systems, flavor combinations, pH adjustment, polymeric taste-masking agents, and ion-exchange or lipid-based approaches. The strategy should avoid excipients with substantial pediatric safety or regulatory complexity unless the commercial benefit is clear.

A liquid with a lower drug concentration could improve dose measurement for small children but would increase administration volume. A more concentrated product would reduce volume but could worsen taste, viscosity, sedimentation, and dose-measurement errors. The target concentration should be selected from actual pediatric dosing ranges and device performance rather than from API loading alone.

Oral syringe-compatible suspension

A commercial product can differentiate through the dosing system rather than the formulation alone. The package should include a calibrated oral syringe with a low dead-space design, a bottle adapter, and clear shaking instructions. Dose delivery studies should evaluate:

• First-dose and end-of-bottle uniformity.
• Doses after short and extended storage intervals.
• Delivery by caregivers with limited dexterity.
• Compatibility with the supplied syringe.
• Residual volume and bottle geometry.

The FDA has emphasized dosing-device performance and clear labeling for liquid medicines, especially where dosing errors can cause clinically significant harm (FDA, 2011).

Sprinkle or dispersible dosage form

A sprinkle capsule or dispersible tablet could address patients who cannot swallow conventional tablets. This route presents technical and regulatory questions:

• Whether felbamate remains chemically and physically stable after dispersion.
• Whether the product can be administered with soft food.
• Whether crushing or opening changes exposure.
• Whether the dose is fully recovered from the food vehicle.
• Whether the formulation creates unacceptable bitterness.
• Whether the dosage form is suitable for enteral tube administration.

A sprinkle product could offer stronger differentiation than a conventional tablet while avoiding the technical burden of a high-water-content suspension. Its value would depend on demonstrating administration reliability and a meaningful patient population.

Orally disintegrating tablet

An orally disintegrating tablet could support patients with swallowing difficulty, but the opportunity is less compelling than a pediatric liquid. Felbamate doses can be relatively high, which may require a large tablet or multiple units. High drug loading can impair tablet strength, mouthfeel, and disintegration. The product could be more attractive at lower strengths for titration, but the commercial market would need to support additional presentations.

Which excipients are most commercially attractive?

The highest-value excipient opportunities involve established, multifunctional materials with broad regulatory acceptance.

Suspending polymers

Xanthan gum, hypromellose, hydroxyethylcellulose, sodium carboxymethylcellulose, and related cellulose derivatives can be screened for sedimentation control and redispersibility. The preferred system should produce a structured vehicle at rest but permit easy pouring or syringe withdrawal under shear.

The key development metrics are sedimentation volume, particle-size distribution, redispersibility cycles, viscosity across shear rates, and dose uniformity. A high-viscosity vehicle may improve suspension stability but impair dosing and caregiver acceptance.

Taste-masking excipients

Sweeteners and flavors are the simplest starting point. If those systems are inadequate, developers could evaluate:

• Ion-exchange resins.
• Polymer coatings.
• Lipid-based barriers.
• Cyclodextrin complexes.
• pH-mediated reduction of taste perception.
• Multiparticulate systems for sprinkle delivery.

The choice should be based on felbamate’s aqueous solubility, pKa, particle properties, and taste threshold. A taste-masking system that delays dissolution or changes exposure would require additional pharmacokinetic evaluation.

Preservative systems

A multidose suspension requires a robust microbial-control strategy. Common approaches include parabens, benzoate systems, sorbate systems, or alternative preservative technologies. The selection must account for pH, excipient compatibility, container adsorption, preservative effectiveness, and pediatric exposure.

A preservative-free product in a unit-dose or multidose airless package could provide differentiation, but packaging costs and manufacturing complexity would increase. The commercial case is stronger where preservative intolerance, caregiver preference, or institutional use justifies the premium.

Buffer systems

Citrate and phosphate buffers can control pH, but buffer choice must be evaluated against chemical stability, palatability, preservative performance, and compatibility with packaging. The target pH should be selected through degradation-pathway studies rather than taste alone.

What regulatory pathway would apply to a new felbamate formulation?

A conventional generic tablet would normally use an abbreviated new drug application pathway if the product meets applicable requirements for sameness, bioequivalence, dosage form, strength, route, labeling, and quality. A new suspension, sprinkle product, or orally disintegrating dosage form may require a more complex regulatory strategy.

Product concept	Likely regulatory issue
Conventional tablet generic	ANDA, with bioequivalence and pharmaceutical equivalence
New concentration suspension	ANDA only if product requirements can be met; otherwise greater development burden
New dosage form	Potential 505(b)(2) pathway or other FDA-supported route
New excipient system	Safety qualification, compatibility, stability, and possible clinical bridging
New device-enabled liquid	Combination-product and dosing-device requirements
New indication	Separate clinical and labeling strategy

A 505(b)(2) application could be relevant when the proposed product differs materially from the listed drug in dosage form, formulation, concentration, or delivery system but relies partly on FDA findings for felbamate. The pathway does not eliminate the need to establish product quality, safety, and appropriate exposure. FDA guidance identifies formulation changes, dosage-form changes, and new delivery technologies as common 505(b)(2) subjects (FDA, 2019).

The serious safety profile makes labeling and risk communication central to development. A new formulation cannot be positioned as reducing felbamate’s intrinsic risk without evidence. The product must preserve warnings, monitoring recommendations, and contraindication language unless FDA approves a change.

What patent protection and exclusivity apply to felbamate?

Felbamate is an older active ingredient, and the principal commercial barriers are regulatory, clinical, manufacturing, and market-size constraints rather than a modern composition-of-matter patent estate.

Orange Book status and generic entry

FDA’s Orange Book is the primary public source for approved products, therapeutic-equivalence evaluations, patent listings, and regulatory exclusivity information (FDA, 2024b). For an older felbamate product, commercial diligence should distinguish between:

• Patents listed for the reference product.
• Regulatory exclusivity remaining for a specific application.
• Patents covering a particular suspension, device, or reformulation.
• Unlisted process, supplier, trade-secret, or know-how protections.
• State or federal controlled-substance restrictions, if any.

A conventional felbamate generic is unlikely to face a meaningful new chemical entity exclusivity barrier. Paragraph IV exposure is more relevant to any later-developed formulation patent, particularly a novel pediatric suspension, taste-masked product, device combination, or modified-release system.

Formulation patents

A new excipient system could support patent claims directed to:

• Felbamate particle-size distributions.
• Specific suspending-polymer combinations.
• Preservative-free multidose packaging.
• Defined pH and viscosity ranges.
• Taste-masked particles.
• Sprinkle or tube-administration methods.
• Oral syringe and bottle configurations.
• Stability after repeated opening.
• Manufacturing methods that improve content uniformity.

Patent strength would depend on whether the formulation solves a demonstrated technical problem and whether competitors can design around the claimed excipient ranges. Broad claims covering routine combinations of standard excipients may face significant validity and obviousness risk.

Method-of-use patents

Potential method-of-use claims could address administration in pediatric epilepsy, enteral-tube delivery, or a specific patient subgroup. Their commercial value would be limited if physicians can prescribe the product for the same clinical use under existing felbamate labeling or if generic labeling omits a protected indication through a section viii strategy.

When does felbamate lose exclusivity?

Felbamate’s core exclusivity period has long elapsed. The relevant commercial question is not the expiration of the original molecule patent but whether a later product has enforceable formulation, use, device, or process rights.

Exclusivity category	Commercial relevance
Original composition-of-matter protection	Historical; no longer the primary barrier
NCE exclusivity	Expired for this older product
Pediatric exclusivity	Historical or product-specific; requires Orange Book confirmation
Formulation patents	Relevant only to later-developed products
Method-of-use patents	Potentially relevant to protected indications
Orphan exclusivity	May apply only if separately granted for a qualifying indication
Regulatory exclusivity for reformulation	Depends on the approved application and FDA designation

A developer should treat any new felbamate product as an intellectual-property project separate from the legacy tablet. A differentiated liquid or device could create new patentable subject matter, but the patent term would begin from the later filing date and would not restore exclusivity to the active ingredient.

What are the principal manufacturing and IP barriers?

The manufacturing barriers are manageable but meaningful.

API and impurity control

Felbamate API supply must support tight control of identity, assay, related substances, residual solvents, particle size, and microbiological quality. For suspension development, API particle size and morphology can directly affect sedimentation, dissolution, taste, and dose uniformity.

Suspension uniformity

The most important process variables include:

• Wetting and deagglomeration.
• Milling or particle-size control.
• Order of excipient addition.
• Hydration of polymers.
• Homogenization energy.
• Hold time before filling.
• Fill-line agitation.
• Bottle-fill accuracy.

A scale-up process that performs in laboratory vessels may produce different viscosity and sedimentation behavior at commercial scale. Process analytical technology can help monitor viscosity, particle size, and content uniformity during development (International Council for Harmonisation [ICH], 2009).

Packaging

The product should be tested in the intended commercial bottle and closure system. Key risks include sorption of felbamate or preservatives, leachables from elastomers, light exposure, oxygen ingress, and changes in suspension structure over time. FDA guidance supports systematic evaluation of container-closure systems and extractables and leachables where relevant (FDA, 1999).

Intellectual-property barriers

A formulation patent is strongest when it links a defined excipient system to measurable performance, such as improved redispersibility, reduced sedimentation, superior taste, or consistent dosing after storage. A specification that merely lists common excipients without a demonstrated technical effect is more vulnerable to challenge.

Which companies could compete in felbamate?

Competition is likely to come from established generic manufacturers, specialty pharmaceutical companies, and contract development and manufacturing organizations rather than large innovative pharmaceutical companies.

Potential competitor groups include:

1. Manufacturers of generic felbamate tablets.
2. Companies holding or supplying legacy oral suspension products.
3. Specialty epilepsy companies seeking niche lifecycle-management products.
4. CDMOs with pediatric liquid and high-containment capabilities.
5. Excipient suppliers offering suspension, taste-masking, or preservative technologies.
6. Pharmaceutical packaging companies providing oral syringe and bottle systems.

The market is unlikely to support many differentiated products. A company would need either reliable supply, a lower total treatment cost, superior pediatric usability, or a defensible regulatory and patent position.

What revenue exposure and commercial opportunity exist?

Felbamate is a niche product with limited broad-market revenue potential. Its value is concentrated in patients with severe or refractory epilepsy, especially Lennox-Gastaut syndrome and patients requiring complex medication regimens.

Attractive commercial segments

Segment	Opportunity
Pediatric epilepsy	Strongest formulation opportunity because of swallowing and adherence needs
Dysphagia patients	Liquid or dispersible dosage forms
Enteral-tube administration	Specialized suspension or dispersible product
Hospital and institutional care	Standardized dosing device and reliable supply
Specialty pharmacy	Patient-support and monitoring services
International markets	Local availability gaps and dosage-form substitution
Contract manufacturing	Pediatric liquid development and fill-finish services

The commercial thesis is stronger for a low-investment reformulation than for a large clinical program. A sponsor could pursue a focused product using existing safety and efficacy knowledge, with development spending directed toward formulation, bioavailability, usability, stability, and regulatory documentation.

The major downside is market contraction caused by newer antiseizure medicines with more favorable safety profiles. Any investment case should model low patient volume, price pressure from generic tablets, and the possibility that prescribers continue using alternative drugs even if a better formulation becomes available.

How does felbamate compare with competing antiseizure drugs?

Felbamate’s differentiation is clinical niche utility rather than tolerability or convenience.

Drug	Main formulation advantage	Commercial implication
Felbamate	Existing tablet and liquid options; refractory-use positioning	Niche market with safety-driven prescribing limits
Rufinamide	Pediatric liquid and tablet options for Lennox-Gastaut syndrome	Stronger syndrome-specific competition
Clobazam	Liquid and tablet availability in several markets	Competes for Lennox-Gastaut treatment
Cannabidiol	Oral solution with high pediatric recognition	Competes in refractory epilepsy but has interaction and monitoring considerations
Valproate	Broad dosage-form availability	Lower formulation differentiation, but broader clinical use
Lamotrigine	Multiple dosage forms and strengths	Strong titration and chronic-use convenience

A felbamate reformulation would need to compete against products that already have pediatric liquids, better-established prescribing patterns, or broader indication coverage. The product should therefore target an administration problem that competing therapies do not solve adequately.

What generic launch scenarios exist?

Three launch scenarios are commercially plausible.

Scenario 1: Low-cost conventional generic

A manufacturer launches standard-strength tablets using established excipients. This requires the lowest formulation investment but faces the greatest price competition. Supply reliability and manufacturing cost are the main differentiators.

Scenario 2: Pediatric oral suspension

A company launches a palatable, syringe-compatible suspension with improved redispersibility and dosing instructions. This has a better chance of preserving margin but requires formulation, stability, usability, and potentially bioequivalence work.

Scenario 3: Protected lifecycle product

A sponsor develops a patented taste-masked, sprinkle, tube-compatible, or preservative-free product. This offers the strongest differentiation and potential for a 505(b)(2) strategy but carries higher clinical, regulatory, manufacturing, and patent risk.

A Paragraph IV challenge would be most likely against patents covering a later reformulation rather than the legacy felbamate molecule. Settlement agreements could affect launch timing if a formulation patent is listed and successfully asserted, but no general settlement conclusion should be assumed without reviewing the relevant litigation docket and agreement.

Key Takeaways

• Felbamate is an old, low-volume antiseizure drug with a commercially narrow but clinically important patient population.
• The best excipient opportunity is a pediatric oral suspension with improved taste, redispersibility, dosing accuracy, and package usability.
• Conventional tablet excipient changes have limited standalone commercial value.
• Suspending polymers, taste-masking systems, preservatives, buffers, and dosing devices are the main formulation-development levers.
• The serious safety profile limits market expansion and prevents a formulation from being positioned as intrinsically safer without clinical evidence.
• Core molecule exclusivity is no longer the primary barrier. New formulation, device, method-of-use, and process patents would determine later exclusivity.
• A differentiated suspension or sprinkle product could support an ANDA or 505(b)(2) strategy, depending on the extent of the formulation and dosage-form changes.
• Commercial upside is limited by generic price pressure, competing pediatric products, and the availability of newer antiseizure therapies.
• Manufacturing expertise in pediatric liquids, particle-size control, suspension processing, and package-device integration is likely to create more value than a routine excipient substitution.

FAQs

Can felbamate be formulated without preservatives?

Yes, but a preservative-free product would require an alternative microbial-control strategy, such as unit-dose packaging, aseptic manufacture, or a validated multidose container system. The commercial benefit must justify higher packaging and manufacturing costs.

Which excipient is best for a felbamate suspension?

No single excipient is universally optimal. Xanthan gum and cellulose derivatives are reasonable screening candidates because they can provide suspension structure and shear-thinning behavior. The final choice depends on sedimentation, redispersibility, taste, stability, and syringe performance.

Could a felbamate liquid qualify as a 505(b)(2) product?

Potentially. A materially different concentration, dosage form, delivery system, or excipient architecture may support a 505(b)(2) strategy if the application can rely partly on FDA findings for an approved felbamate product. The sponsor would still need to establish product-specific quality and exposure.

Is felbamate suitable for an orally disintegrating tablet?

It may be technically feasible, but the relatively high dose can create tablet-size, taste, strength, and disintegration challenges. A dispersible or sprinkle dosage form may provide greater practical value for patients with swallowing difficulty.

What is the most defensible patent strategy for a new felbamate formulation?

The strongest strategy would connect a defined excipient and manufacturing system to measured performance benefits, such as sustained dose uniformity after storage, improved redispersibility, reduced bitterness, or reliable enteral-tube delivery. Broad claims covering routine excipient combinations would be more vulnerable to design-around and validity challenges.

References

DailyMed. (2024). Felbamate: Prescribing information and inactive ingredients. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

International Council for Harmonisation. (2009). ICH Q8(R2): Pharmaceutical development. https://www.ich.org/

U.S. Food and Drug Administration. (1999). Container closure systems for packaging human drugs and biologics. https://www.fda.gov/

U.S. Food and Drug Administration. (2011). Guidance for industry: Dosage delivery devices for orally ingested OTC liquid drug products. https://www.fda.gov/

U.S. Food and Drug Administration. (2019). Applications covered by section 505(b)(2). https://www.fda.gov/

U.S. Food and Drug Administration. (2024a). Felbatol prescribing information. https://www.accessdata.fda.gov/

U.S. Food and Drug Administration. (2024b). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/ index.cfm